Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications
Neoadjuvant Tyrosine Kinase Inhibitors.
Journal: Thoracic surgery clinics
Published: November 19, 2025
CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer.
Journal: bioRxiv : the preprint server for biology
Published: November 19, 2025
Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity.
Journal: bioRxiv : the preprint server for biology
Published: August 13, 2025
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 02, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Journal: Nature
Published: February 27, 2025
Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer.
Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 06, 2025
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study.
Journal: Future oncology (London, England)
Published: November 08, 2024
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 19, 2024
Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.
Journal: The oncologist
Published: July 03, 2024
Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.
Journal: Clinical lung cancer
Published: April 27, 2024
Targeting MEK in non-small cell lung cancer.
Journal: Current problems in cancer
Published: January 06, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Journal: Nature
Published: October 27, 2023
Last Updated: 09/26/2026